Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The gut microbiota composition and intestinal epithelial interface represents the complex, bidirectional communication system between the trillions of microorganisms in the gastrointestinal tract and the host's epithelial lining. This interface serves as a critical physical and biochemical barrier that regulates the passage of nutrients and water while preventing the translocation of pathogens and toxins into the systemic circulation (NIH, 2025; MDPI, 2020). The microbiota influences the integrity of this barrier through the production of metabolites, such as short-chain fatty acids (SCFAs), which provide energy to colonocytes and promote the expression of tight junction proteins like zonula occludens-1 (ZO-1) (NIH, 2022). Specialized epithelial cells, including Paneth and goblet cells, further contribute to this interface by secreting antimicrobial peptides and mucins that shape the microbial environment (Karger, 2016; NIH, 2025). Dysregulation of this interface, often characterized by microbial dysbiosis and increased intestinal permeability, is a hallmark of various diseases, including inflammatory bowel disease, metabolic syndrome, and colorectal cancer (MDPI, 2020; NIH, 2025). Therapeutic strategies targeting this system include the use of probiotics, prebiotics, and fecal microbiota transplantation to restore microbial balance and reinforce the intestinal barrier (MDPI, 2024; NIH, 2022). Additionally, the interface plays a vital role in the maturation and regulation of the host's mucosal immune system, making it a focal point for developing precision medicine approaches for gastrointestinal and systemic disorders (NIH, 2022; NIH, 2025).
Modulation of microbial diversity and abundance, enhancement of tight junction protein expression (e.g., ZO-1, occludin), and production of bioactive metabolites like short-chain fatty acids (SCFAs) to maintain mucosal integrity and regulate host immune responses.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gut microbiota composition and intestinal epithelial interface.